Sulbactam sodiumCAS# 69388-84-7 |
- Hyoscyamine
Catalog No.:BCN1946
CAS No.:101-31-5
- Neostigmine Bromide
Catalog No.:BCC4563
CAS No.:114-80-7
- Tropicamide
Catalog No.:BCC4574
CAS No.:1508-75-4
- Otilonium Bromide
Catalog No.:BCC4573
CAS No.:26095-59-0
- Flavoxate hydrochloride
Catalog No.:BCC5208
CAS No.:3717-88-2
- Homatropine Methylbromide
Catalog No.:BCC4571
CAS No.:80-49-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 69388-84-7 | SDF | Download SDF |
| PubChem ID | 23663973 | Appearance | Powder |
| Formula | C8H10NNaO5S | M.Wt | 255.22 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | sodium;(2S,5R)-3,3-dimethyl-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate | ||
| SMILES | CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)[O-])C.[Na+] | ||
| Standard InChIKey | NKZMPZCWBSWAOX-IBTYICNHSA-M | ||
| Standard InChI | InChI=1S/C8H11NO5S.Na/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14;/h5-6H,3H2,1-2H3,(H,11,12);/q;+1/p-1/t5-,6+;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Sulbactam sodium Dilution Calculator
Sulbactam sodium Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.9182 mL | 19.5909 mL | 39.1819 mL | 78.3638 mL | 97.9547 mL |
| 5 mM | 0.7836 mL | 3.9182 mL | 7.8364 mL | 15.6728 mL | 19.5909 mL |
| 10 mM | 0.3918 mL | 1.9591 mL | 3.9182 mL | 7.8364 mL | 9.7955 mL |
| 50 mM | 0.0784 mL | 0.3918 mL | 0.7836 mL | 1.5673 mL | 1.9591 mL |
| 100 mM | 0.0392 mL | 0.1959 mL | 0.3918 mL | 0.7836 mL | 0.9795 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Sulbactam sodium
- Schisanhenol
Catalog No.:BCN2508
CAS No.:69363-14-0
- Pendulone
Catalog No.:BCN8248
CAS No.:69359-09-7
- Boc-D-Thr(Bzl)-OH
Catalog No.:BCC3454
CAS No.:69355-99-3
- Galanthamine hydrochloride
Catalog No.:BCC8277
CAS No.:5072-47-9
- Obtucarbamate A
Catalog No.:BCN3936
CAS No.:6935-99-5
- 2-Benzylaminopyridine
Catalog No.:BCC8565
CAS No.:6935-27-9
- CPPHA
Catalog No.:BCC1501
CAS No.:693288-97-0
- CYC116
Catalog No.:BCC2181
CAS No.:693228-63-6
- H-Ile-OtBu.HCl
Catalog No.:BCC2965
CAS No.:69320-89-4
- (R)-baclofen
Catalog No.:BCC4503
CAS No.:69308-37-8
- 12-Aminolauric acid
Catalog No.:BCC8436
CAS No.:693-57-2
- 3-beta-O-(cis-p-Coumaroyl)maslinic acid
Catalog No.:BCN1375
CAS No.:69297-40-1
- Lappaol H
Catalog No.:BCN8415
CAS No.:69394-18-9
- Amonafide
Catalog No.:BCC1249
CAS No.:69408-81-7
- SB505124
Catalog No.:BCC5087
CAS No.:694433-59-5
- 17-PA
Catalog No.:BCC7452
CAS No.:694438-95-4
- Parvifuran
Catalog No.:BCN7780
CAS No.:69470-93-5
- 2-Methyl-4-isobutyrylphloroglucinol
Catalog No.:BCN7176
CAS No.:69480-03-1
- Boc-D-His(Tos)-OH
Catalog No.:BCC3405
CAS No.:69541-68-0
- Thymopentin
Catalog No.:BCN8347
CAS No.:69558-55-0
- Octadecyl caffeate
Catalog No.:BCN6609
CAS No.:69573-60-0
- Tupichilignan A
Catalog No.:BCN4257
CAS No.:69586-96-5
- 4-Hydroxybenzylamine
Catalog No.:BCN1805
CAS No.:696-60-6
- CRT0044876
Catalog No.:BCC5109
CAS No.:6960-45-8
Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam.[Pubmed:28099605]
An Bras Dermatol. 2016 Nov-Dec;91(6):808-810.
Acute localized exanthematous pustulosis is a localized variant of acute generalized exanthematous pustulosis, which is characterized by the eruption of multiple scattered pustules following drug administration. A 72-year-old woman presented with multiple erythematous pustules on her face, which had appeared two days after using cefoperazone and sodium sulbactam. Histopathological findings showed subcorneal pustules and mixed inflammatory cell infiltration in the dermis. The pustules resolved within about two weeks after the patient discontinued the antibiotics. This report discusses the case of a woman with a cutaneous drug reaction consistent with acute localized exanthematous pustulosis that occurred after cefoperazone and sodium sulbactam were administered.
A new fractional wavelet approach for the simultaneous determination of ampicillin sodium and sulbactam sodium in a binary mixture.[Pubmed:16024281]
Spectrochim Acta A Mol Biomol Spectrosc. 2006 Mar 1;63(3):631-8.
A new application of the fractional wavelet transform (FWT) was proposed for the simultaneous determination of ampicillin (AP) and sulbactam (SB) in a pharmaceutical combination for injection. FWT approach is a new powerful tool for removing noise and irrelevant information from the absorption spectra. Cardinal information having higher peak amplitude, eliminated noise, sharp peaks with shrinking width of spectral range was obtained by the application of FWT procedure to the original absorption spectra. In this paper, FWT approach was subjected to the data vector of the UV-signals obtained from AP and SB in the wavelength range of 211.5-313.8 nm. Derivative transform was applied to the original absorption signal together with its FWT generalization. The calibration graphs for AP and SB were obtained by measuring the FWT and usual derivative amplitudes at zero-crossing points. The method validation was carried out by using the synthetic mixture analysis. Our proposed FWT approach was compared with the usual derivative spectrophotometry and chemometric methods (CLS, PCR and PLS) and a good agreement was reported.
[The clinical evaluation of piperacillin and sulbactam sodium in treatment of respiratory, urinary tracts and other infections in 579 patients].[Pubmed:22041274]
Zhonghua Nei Ke Za Zhi. 2011 Jul;50(7):601-3.
OBJECTIVE: To evaluate the clinical efficacy and safety of piperacillin and Sulbactam sodium combinations in the treatment of common infections. METHODS: This was a multi-centre, prospective and open study. All subjects from 57 wards caught common infection like respiratory (RTI) or urinary diseases (UTI). The dosages of piperacillin and Sulbactam sodium combinations 2.5 g injection were determined according to indications: for adult, 2.5 g or 5 g per time, 2 time/day; for severe or obstinate infection, 2.5 g or 5 g per time, 3 time/day. General information, clinical response pre- and post-treatment, infected locus, drug recipe and protocol, prognosis and adverse reaction were recorded. RESULTS: Data of 579 cases were collected with 388 males and 191 females. The average age was (66.8 +/- 17.0) years. There were 500 patients who were suffering with RTI, with 362 cases of pneumonia, 102 of acute exacerbation of chronic bronchitis, and 36 of other infections. There were 50 cases with UTI, with 31 of simple urinary tract infection, and 19 of complex urinary tract infection. In addition, there were 9 cases of combined RTI and UTI, and 20 of other infections including peritonitis. The average duration of anti-microbial for RTI and UTI was (8.65 +/- 3.78) days and (7.45 +/- 3.46) days respectively with the total efficacy rate was 92.6% and 98.0% respectively for RTI and UTI. The incidence of adverse events was only 0.86% (5 cases), including nausea, rash, itching, ALT elevation and suspected drug induced fever in each one. CONCLUSION: Piperacillin and Sulbactam sodium compound had high clinical efficacy and safety in the treatment of common infections including RTI and UTI.
Ultraviolet spectrophotometry (dual wavelength and chemometric) and high performance liquid chromatography for simultaneous estimation of meropenem and sulbactam sodium in pharmaceutical dosage form.[Pubmed:24495837]
Spectrochim Acta A Mol Biomol Spectrosc. 2014 Apr 24;124:292-9.
UV spectrophotometric and high performance liquid chromatography (HPLC) methods were developed for simultaneous determination of meropenem (MERM) and Sulbactam sodium (SB) in injection. UV spectrophotometric methods were developed using 0.1N sodium hydroxide as solvent. The Beer's plot for dual wavelength method was linear in the range of 4-24 mug mL(-1) and 2-12 mug mL(-1) for MERM and SB, respectively. The percent recoveries were found to be 98.52+/-1.23% for MERM and 101.45+/-1.1% for SB. Chemometrics assisted UV spectrophotometry was performed using Partial Least Square (PLS) analysis model and Principal Component Regression (PCR) analysis model. The % recoveries of the MERM were found to be 100.61+/-0.06% and 101.31+/-0.12% using PLS and PCR, respectively. The % recoveries of the SB were found to be 98.29+/-0.09% and 97.61+/-0.13% using PLS and PCR, respectively. Chromatography was performed on Hypersil BDS C18 column using methanol:acetonitrile:water (10:20:70 v/v/v) as mobile phase. The retention times of MERM and SB were found to be 2.9 min and 2.25 min, respectively. Developed HPLC method was found to be linear in the range of 50-250 mug mL(-1) and 25-125 mug mL(-1) for MERM and SB, respectively. The % recoveries were found to be 98.85+/-0.25% and 98.63+/-0.34% for MERM and SB, respectively. The developed analytical methods did not show any interference of the excipients when applied to pharmaceutical dosage form.
